2013
Sheehan Suicidality Tracking Scale (S-STS): Reliability, convergent and discriminative validity in young Italian adults
Preti A, Sheehan D, Coric V, Distinto M, Pitanti M, Vacca I, Siddi A, Masala C, Petretto D. Sheehan Suicidality Tracking Scale (S-STS): Reliability, convergent and discriminative validity in young Italian adults. Comprehensive Psychiatry 2013, 54: 842-849. PMID: 23618606, DOI: 10.1016/j.comppsych.2013.03.012.Peer-Reviewed Original ResearchConceptsSuicidal behaviorSheehan Suicidality Tracking ScaleS-STSTreatment-emergent suicidal ideationPsychological distressClinician-Administered Rating ScaleSocial supportTest-retest stabilitySuicide ideationDivergent validityInternal consistencyCross-sectional designHigh riskSuicidal ideationScreening toolRating Scale
2012
Safety and Tolerability of the γ-Secretase Inhibitor Avagacestat in a Phase 2 Study of Mild to Moderate Alzheimer Disease
Coric V, van Dyck CH, Salloway S, Andreasen N, Brody M, Richter RW, Soininen H, Thein S, Shiovitz T, Pilcher G, Colby S, Rollin L, Dockens R, Pachai C, Portelius E, Andreasson U, Blennow K, Soares H, Albright C, Feldman HH, Berman RM. Safety and Tolerability of the γ-Secretase Inhibitor Avagacestat in a Phase 2 Study of Mild to Moderate Alzheimer Disease. JAMA Neurology 2012, 69: 1430-1440. PMID: 22892585, DOI: 10.1001/archneurol.2012.2194.Peer-Reviewed Original ResearchMeSH KeywordsActivities of Daily LivingAgedAged, 80 and overAlzheimer DiseaseAmyloid beta-PeptidesAmyloid Precursor Protein SecretasesBody WeightDose-Response Relationship, DrugDouble-Blind MethodEnzyme InhibitorsFemaleHumansImmunoprecipitationInternational CooperationMagnetic Resonance ImagingMaleMass SpectrometryMiddle AgedNeuropsychological TestsOutcome Assessment, Health CareOxadiazolesPsychiatric Status Rating ScalesSulfonamidesTau ProteinsTime FactorsConceptsPhase 2 studyModerate Alzheimer's diseaseAdverse eventsAlzheimer's diseaseDiscontinuation ratesDose groupPharmacodynamic effectsAlzheimer's Disease Assessment Scale-cognitive subscale scoresTreatment-emergent serious adverse eventsDouble-blind treatment phaseΓ-Secretase Inhibitor AvagacestatSerious adverse eventsLow discontinuation rateNonmelanoma skin cancerCognitive subscale scoresDose armBiomarker substudyMedian ageMulticenter trialAcceptable safetyCognitive worseningΕ4 carriersCommon reasonTreatment groupsTreatment phase